A retrospective study of the CHOP, CHOPE, and CHOPE/G regimens as the first-line treatment of peripheral T-cell lymphomas

[1]  Anna Bowzyk Al-Naeeb,et al.  Non-Hodgkin lymphoma , 2018, British Medical Journal.

[2]  S. Montoto,et al.  CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trial , 2018, The Lancet. Haematology.

[3]  S. Swerdlow.  WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues , 2017 .

[4]  P. Liu,et al.  Comparison of gemcitabin, cisplatin, and dexamethasone (GDP), CHOP, and CHOPE in the first-line treatment of peripheral T-cell lymphomas , 2016, Hematology.

[5]  W. Wilson,et al.  Phase II trial of dose-adjusted EPOCH in untreated systemic anaplastic large cell lymphoma , 2016, Haematologica.

[6]  Bruce D Cheson,et al.  Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  M. Jerkeman,et al.  Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry. , 2014, Blood.

[8]  Randy D Gascoyne,et al.  Non-Hodgkin lymphoma , 2016, Medicine.

[9]  Y. Ko,et al.  Peripheral T cell lymphoma in Asia , 2014, International Journal of Hematology.

[10]  D. Weisenburger,et al.  Differences in incidence and trends of haematological malignancies in Japan and the United States , 2013, British journal of haematology.

[11]  He Huang,et al.  Significance of clinical factors as prognostic indicators for patients with peripheral T-cell non-Hodgkin lymphoma: A retrospective analysis of 252 cases , 2013, Molecular and clinical oncology.

[12]  P. Liu,et al.  Gemcitabine-based combination regimen in patients with peripheral T-cell lymphoma , 2013, Medical Oncology.

[13]  R. Fisher,et al.  Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T‐cell non‐Hodgkin lymphoma , 2013, Cancer.

[14]  Kate R Shankland,et al.  Non-Hodgkin lymphoma , 2012, The Lancet.

[15]  A. Rosenwald,et al.  Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. , 2010, Blood.

[16]  S. Pileri,et al.  Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  M. Ziepert,et al.  High-dose CHOP plus etoposide (MegaCHOEP) in T-cell lymphoma: a comparative analysis of patients treated within trials of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  John R. Krause,et al.  WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues: An Overview , 2009 .

[19]  D. Weisenburger,et al.  International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  A. Horwich,et al.  Gemcitabine, cisplatin and methylprednisolone for the treatment of patients with peripheral T-cell lymphoma: the Royal Marsden Hospital experience. , 2007, Haematologica.

[21]  Je-Jung Lee,et al.  CHOP plus etoposide and gemcitabine (CHOP-EG) as front-line chemotherapy for patients with peripheral T cell lymphomas , 2006, Cancer Chemotherapy and Pharmacology.

[22]  Terry L. Smith,et al.  Prognostic factors and treatment of patients with T‐cell non‐Hodgkin lymphoma , 2005, Cancer.

[23]  B. Nathwani,et al.  Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin's Lymphoma Classification Project. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  S. Pileri,et al.  Peripheral T-cell lymphomas. Clinico-pathologic study of 168 cases diagnosed according to the R.E.A.L. Classification. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  E. Campo,et al.  The World Health Organization Classification of Lymphoid Neoplasms , 2013 .

[26]  D. Weisenburger,et al.  Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. , 2006, Blood.